In the United States, about 62% of Medicare recipients ages 65 to 74 years have multiple chronic conditions (MCC; ? 2 chronic conditions), and the frequency increases dramatically to 82% above age 85. Because adults with MCC are at increased risk of functional decline and are particularly vulnerable to poor care, MCC threatens both the public and financial health of the United States. MCC prevalence may be reduced by delaying the onset of single conditions and combinations of conditions through modification of risk factors or determinants of diseases. However, current preventive efforts have partly failed because they have focused on one disease at a time and too late in life. For this reason, there is a critical need to identify groups of individuals at risk earlier in life, and to develop interventions to prevent MCC and their adverse health outcomes. These priorities were outlined in the Multiple Chronic Conditions Strategic Framework of the US Department of Health and Human Services (DHHS) of 2010. A growing body of literature has described patterns of prevalent MCC in the United States and worldwide; however, the patterns of incidence of MCC and the outcomes of MCC remain poorly understood. In addition, the National Institute on Aging has recommended the novel approach of considering MCC as a proxy measure (clinical marker) of accelerated aging. Therefore, we will study the incidence and the rate of accumulation of MCC and the health outcomes of MCC across the entire life span. The Rochester Epidemiology Project (REP) is an ideal environment to study the incidence and rate of accumulation of MCC, and the outcomes of MCC because it includes information for all ages from new- borns to death, regardless of insurance status or health care setting, and encompasses the full spectrum of care, from primary to tertiary care. In this application, we propose to study the incidence and life course accumulation of MCC using 18 selected somatic and mental health conditions across all ages (Aim 1), to study the short-term and long-term medical-records-based adverse health outcomes of incident MCC (Aim 2), and to study the short-term and long-term patient reported adverse outcomes of incident MCC (Aim 3). Understanding the incidence and accumulation of MCC, and its objective and subjective health outcomes is critical to enabling clinical and public health agencies to prevent and treat MCC, and to improve population health. In addition, these studies will identify persons at high risk of developing MCC early in life (accelerated aging). These persons may be selected for future studies of biomarkers (e.g., blood tests, genetic tests, imaging) or for preventive interventions to slow aging (e.g., specific drugs, dietary modification, lifestyle modification). Studying MCC as a clinical marker will advance our understanding of aging. In summary, the studies proposed here are novel, can be efficiently conducted using the REP, and are urgently needed.

Public Health Relevance

We propose to study the incidence and life course accumulation of multiple chronic conditions (MCC) and the adverse health outcomes of newly developed MCC using the records-linkage system of the unique Rochester Epidemiology Project. Our ultimate goal is to understand accelerated aging, to guide the prevention of MCC, and to improve health outcomes for persons affected by MCC. The studies proposed here are novel, can be efficiently conducted using the Rochester Epidemiology Project, and are urgently needed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG052425-01A1
Application #
9237976
Study Section
Aging Systems and Geriatrics Study Section (ASG)
Program Officer
Salive, Marcel
Project Start
2017-04-01
Project End
2022-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
1
Fiscal Year
2017
Total Cost
$667,531
Indirect Cost
$244,703
Name
Mayo Clinic, Rochester
Department
Type
Other Domestic Non-Profits
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Rocca, Walter A (2018) The future burden of Parkinson's disease. Mov Disord 33:8-9
Savica, Rodolfo; Grossardt, Brandon R; Rocca, Walter A et al. (2018) Parkinson disease with and without Dementia: A prevalence study and future projections. Mov Disord 33:537-543
Rocca, Walter A; Gazzuola Rocca, Liliana; Smith, Carin Y et al. (2018) Personal, reproductive, and familial characteristics associated with bilateral oophorectomy in premenopausal women: A population-based case-control study. Maturitas 117:64-77
Laughlin-Tommaso, Shannon K; Khan, Zaraq; Weaver, Amy L et al. (2018) Cardiovascular and metabolic morbidity after hysterectomy with ovarian conservation: a cohort study. Menopause 25:483-492
Wenning, Gregor; Trojanowski, John Q; Kaufmann, Horacio et al. (2018) Is multiple system atrophy an infectious disease? Ann Neurol 83:10-12
Kattah, Andrea G; Smith, Carin Y; Gazzuola Rocca, Liliana et al. (2018) CKD in Patients with Bilateral Oophorectomy. Clin J Am Soc Nephrol 13:1649-1658
St Sauver, Jennifer L; Grossardt, Brandon R; Finney Rutten, Lila J et al. (2018) Rochester Epidemiology Project Data Exploration Portal. Prev Chronic Dis 15:E42
Bower, James H; Grossardt, Brandon R; Rocca, Walter A et al. (2018) Prevalence of and indications for antipsychotic use in Parkinson's disease. Mov Disord 33:325-328
Rocca, Walter A; Grossardt, Brandon R; Brue, Scott M et al. (2018) Data Resource Profile: Expansion of the Rochester Epidemiology Project medical records-linkage system (E-REP). Int J Epidemiol 47:368-368j
Rocca, Walter A; Gazzuola Rocca, Liliana; Smith, Carin Y et al. (2017) Cohort profile: the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA). BMJ Open 7:e018861

Showing the most recent 10 out of 15 publications